Clinical Trial Update: CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of CPX-351 (Vyxeos) for newly diagnosed high-risk acute myeloid leukemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Arising From Myelodysplastic Syndrome

Drugs mentioned

• Vyxeos (CPX-351)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2021-01-14